Currently, the EGFR (epidermal growth factor receptor) blocking antibodies Cetuximab and Panitumumab are approved for the treatment of metastatic CRC in combination with chemotherapy or as a maintenance therapy in chemo-refractory tumors [2], [3]. Here, EGFR is linked to colorectal carcinoma.